CLINICAL TRIALS PROFILE FOR RECTIV
✉ Email this page to a colleague
All Clinical Trials for RECTIV
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01920074 ↗ | Pharmacokinetic,Safety and Exploratory Efficacy of RECTIV® in Adolescents With Chronic Anal Fissure | Withdrawn | Forest Laboratories | Phase 4 | 2013-06-01 | RECTIV® is an ointment containing 0.4% nitroglycerin (NTG) for the treatment of moderate to severe pain associated with chronic anal fissure approved in June 2011 by the US Food and Drug Administration (FDA) for adults. The purpose of this study is to assess the safety, pharmacokinetics, and exploratory efficacy of RECTIV® in adolescents |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RECTIV
Condition Name
Clinical Trial Locations for RECTIV
Trials by Country
Clinical Trial Progress for RECTIV
Clinical Trial Phase
Clinical Trial Sponsors for RECTIV
Sponsor Name